Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven L Flamm

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
The American Journal of Gastroenterology|April 3, 2023
Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated HepatitisTarek Hassanein, Craig J McClain, Vatsalya Vatsalya, et al.
Journal of Hepatology|April 22, 2014
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trialsJohn M Vierling, Stefan Zeuzem, Fred Poordad, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Annals of Internal Medicine|November 10, 2015
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized TrialStephen Pianko, Steven L Flamm, Mitchell L Shiffman, et al.
Journal of Hepatology|August 12, 2018
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patientsChristoph Sarrazin, Curtis L Cooper, Michael P Manns, et al.
Journal of Vascular and Interventional Radiology : JVIR|December 22, 2020
Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt CreationAndrew C Gordon, Aakash N Gupta, Ahmed Gabr, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisMichael P Curry, Jacqueline G O'Leary, Natalie Bzowej, et al.
Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.
Gastroenterology|May 20, 2015
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseMichael Charlton, Gregory T Everson, Steven L Flamm, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The American Journal of Gastroenterology|April 3, 2023
Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated HepatitisTarek Hassanein, Craig J McClain, Vatsalya Vatsalya, et al.
Journal of Hepatology|April 22, 2014
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trialsJohn M Vierling, Stefan Zeuzem, Fred Poordad, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Annals of Internal Medicine|November 10, 2015
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized TrialStephen Pianko, Steven L Flamm, Mitchell L Shiffman, et al.
Journal of Hepatology|August 12, 2018
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patientsChristoph Sarrazin, Curtis L Cooper, Michael P Manns, et al.
Journal of Vascular and Interventional Radiology : JVIR|December 22, 2020
Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt CreationAndrew C Gordon, Aakash N Gupta, Ahmed Gabr, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisMichael P Curry, Jacqueline G O'Leary, Natalie Bzowej, et al.
Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.
Gastroenterology|May 20, 2015
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseMichael Charlton, Gregory T Everson, Steven L Flamm, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Pageof 7